Business - Briefly   

Ranbaxy gets USFDA nod

MUMBAI: Ranbaxy Pharmaceuticals Inc (RPI) on Tuesday said it had received US Food and Drug Administration's (FDA) approval for manufacturing and marketing the cardiovascular drug, Atenolol tablets, in the U.S.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Cap on roaming tariff `a last resort'
Sensex up 155 points
9.5 p.c. rise in core sector
CII strategy for addressing skills gap in services sector
Real estate boom to gain momentum
Assumes charge
'Holograms provide protection from piracy'
CIAL shows high growth in passenger, aircraft traffic
Rupee edges up
Exchange rates
Bullion rates
Central Bank revises NRE, FCNR (B) rates
BSNL ties up with Department of Post
Special tariff voucher from Reliance
Union Bank's second branch in Tiruchi city
Telecom FDI limit: another extension
TDSAT seeks TRAI view on DTH prices
Review of monetary policy on Jan. 31
Ranbaxy gets USFDA nod

Copyright © 2007, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu